Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: Report of the PSA Committee

BJU International, Supplement

Volumn 92, Issue 2, 2003, Pages 66-70

  Blijenberg, B G ^a   Lilia, H ^b   Neels, H ^c   Stenman, U H ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Laboratory of Clinical Biochemistry   (Belgium)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER RESEARCH; CANCER SCREENING; CONTROLLED STUDY; CORRELATION COEFFICIENT; EUROPE; HEALTH SURVEY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL;

HUMANS; MALE; MULTICENTER STUDIES; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY;

EID: 0347756698     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Denis L, Murphy GP, Schröder FH. Report of the Consensus Workshop on Screening and Global Strategy for Prostate Cancer. Cancer 1995; 75: 1187-207
2. Schröder FH, Denis L, Kirkels W, De Koning HJ, Standaert B. European Study of Screening for Prostate Cancer. Cancer 1995; 76: 129-34
3. Standaert B, Denis L. The European Randomized Study of Screening for Prostate Cancer: an update. Cancer 1997; 80: 1830-4
4. Schröder FH, Van der Maas PJ, Beemsterboer PMM, et al. Evaluation of the digital rectal examination (DRE) as a screening test for prostate cancer. J Natl Cancer Inst 1998; 90: 1817-23
5. Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast TH, Kranse R. PSA based early detection of prostate cancer - validation of screening without rectal examination. Urology 2001; 57: 83-90
6. Laffin RJ, Chan DW, Tansijevic MJ, et al. Hybritech total and free prostatespecific assays developed for the Beckman-Coulter Access automated chemiluminescent immunoassay system: a multicenter evaluation of analytical performance. Clin Chem 2001; 47: 129-32
7. Passing H, Bablok W. A new biomedical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry (Part I). J Clin Chem Clin Biochem 1983; 22: 31-45
8. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307-10
9. Polascik TJ, Oesterling JE, Partin AW. Prostate-specific antigen, a decade of discovery - what we have learned and where we are going. J Urol, 1999; 162: 293-306
10. Milford Ward A, Catto JWF, Hamdy FC. Prostate-specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 2001; 38: 633-51
11. 1,-antichy- motrypsin. Clin Chem 1991; 37: 1618-25
12. 1-antichymotrypsin is the major form of PSA in serum of patients with prostate cancer: assay of the complex improves the clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6
13. Rafferty B, Rigsby P, Rose M, Stamey T, Gaines Das R. Reference reagents for prostate-specific antigen (PSA), establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 2000; 46: 1310-7
14. Anonymous. ISOBM TD-3 International Workshop on monoclonal antibodies against prostate-specific antigen. Tumor Biol 1999; 20: 1-94
15. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schröder FH. Discordant performance of assays for free and total PSA in relation to the early detection of prostate cancer. BJU Int 2001; 88: 545-50
16. Yurdakul G, Bangma CH, Blijenberg BG et al. Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol 2002; 42: 154-8
17. Becker C, Noldus J, Diamandis E, Lilja H. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci 2001; 38: 357-99
18. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59: 797-802
19. Rietbergen JBW, Boeken Kruger AE, Hoedemaker RF, Bangma CH, Kirkels WJ, Schröder FH. Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men: clinical and pathological features of detected cancer. J Urol 1998; 160: 2121-5
20. Komatsu K, Wehner N, Prestigiacomo AF, Chen Z, Stamey TA. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology 1996; 47: 343-6
21. Nixon RG, Wener MH, Smith KM, Parson RE, Strobel SA, Brawer MK. Biological variation of prostate-specific antigen: an evaluation of day-to-day physiological fluctuation in a well-defined cohort of 24 patients. J Urol 1997; 157: 2183-90
22. Ornstein DK, Smith DS, Rao GS, Basler JW, Ratcliff TL, Catalona WJ. Biological variation of total, free and percent free serum prostate-specific antigen levels in screening volunteers. J Urol 1997; 157: 2179-82